Business
enGene Appoints Lee Giguere as Chief Legal Officer and Corporate Secretary
Experienced biotech executive brings public company expertise in legal, corporate governance, and compliance to support enGene during late-stage clinical
About this update from Engene Therapeutics Inc.
[{"type":"text","content":"Experienced biotech executive brings public company expertise in legal, corporate governance, and compliance to support enGene during late-stage clinical development and anticipated future commercial launch of its lead program EG-70\nBOSTON and MONTREAL, Jan. 30, 2024 /PRNewswire/ - enGene Holdings Inc. (\"enGene,\" (Nasdaq: ENGN), a clinical-stage genetic medicines company whose lead program is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the appointment of Lee Giguere as Chief Legal Officer and Corporate Secretary.\n\n \n \n \n \n \n \n\n \n\"I am delighted to welcome Lee, an experienced public biotech legal executive, to enGene as we advance the development of EG-70 in our ongoing pivotal-stage LEGEND study in BCG-unresponsive non-muscle invasive bladder cancer,\" said Jason D. Hanson, Chief Executive Officer of enGene. \"His track record leading the legal function of successful companies, including those navigating late-stage development, product approvals, commercial launches, and strategic transactions, will strongly support our growth.\"\nMr. Giguere previously served as Chief Legal Officer and Secretary of Obsidian Therapeutics, a clinical-stage cell and gene therapy company. Earlier, he was General Counsel and Secretary at Chiasma, where he led the legal, compliance, and human resource functions in support of the approval and launch of the company's acromegaly therapy and played a key role in the subsequent sale of the company. Previously, he was Deputy General Counsel and Assistant Secretary at Karyopharm Therapeutics through the approval and launch of its multiple myeloma therapy. Earlier in his career, Mr. Giguere held roles at Boston Scientific Corporation and in the business law practice of Goodwin Procter LLP. Mr. Giguere earned his Juris Doctor from Northeastern University School of Law and his Bachelor of Science in Business Administration from Northeastern University.\nMr. Giguere commented: \"I am thrilled to join enGene as we work to transform the management of bladder cancer, beginning with BCG-unresponsive NMIBC. With EG-70, enGene has an opportunity to introduce a novel, non-viral, fit-for-purpose class of genetic medicine specifically designed for ease-of-use by the community urologists who are on the front lines of treating this patient group. I look...